AustralieFrV1, PubMed, Corpus, bibRecord, 000A04

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Identifieur interne : 000A04 ( PubMed/Corpus ); précédent : 000A03; suivant : 000A05

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Auteurs : Stanley B. Cohen ; Yoshiya Tanaka ; Xavier Mariette ; Jeffrey R. Curtis ; Eun Bong Lee ; Peter Nash ; Kevin L. Winthrop ; Christina Charles-Schoeman ; Krishan Thirunavukkarasu ; Ryan Demasi ; Jamie Geier ; Kenneth Kwok ; Lisy Wang ; Richard Riese ; Jürgen Wollenhaupt

Source :

Annals of the rheumatic diseases [ 1468-2060 ] ; 2017.

RBID : pubmed:28143815

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid (drug therapy), Clinical Trials as Topic, Female, Herpes Zoster (epidemiology), Herpes Zoster (etiology), Herpes Zoster (immunology), Humans, Immunocompromised Host, Incidence, Infection (epidemiology), Infection (etiology), Infection (immunology), Male, Middle Aged, Neoplasms (epidemiology), Neoplasms (etiology), Neoplasms (immunology), Opportunistic Infections (epidemiology), Opportunistic Infections (etiology), Opportunistic Infections (immunology), Piperidines (adverse effects), Protein Kinase Inhibitors (adverse effects), Pyrimidines (adverse effects), Pyrroles (adverse effects), Time Factors, Tuberculosis (epidemiology), Tuberculosis (etiology), Tuberculosis (immunology), Young Adult.
MESH :
- chemical , adverse effects : Piperidines, Protein Kinase Inhibitors, Pyrimidines, Pyrroles.
- drug therapy : Arthritis, Rheumatoid.
- epidemiology : Herpes Zoster, Infection, Neoplasms, Opportunistic Infections, Tuberculosis.
- etiology : Herpes Zoster, Infection, Neoplasms, Opportunistic Infections, Tuberculosis.
- immunology : Herpes Zoster, Infection, Neoplasms, Opportunistic Infections, Tuberculosis.
- Adolescent, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Female, Humans, Immunocompromised Host, Incidence, Male, Middle Aged, Time Factors, Young Adult.

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.

DOI: 10.1136/annrheumdis-2016-210457
PubMed: 28143815

Links to Exploration step

pubmed:28143815

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.</title>
<author><name sortKey="Cohen, Stanley B" sort="Cohen, Stanley B" uniqKey="Cohen S" first="Stanley B" last="Cohen">Stanley B. Cohen</name>
<affiliation><nlm:affiliation>Metroplex Clinical Research Center, Dallas, Texas, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name>
<affiliation><nlm:affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name>
<affiliation><nlm:affiliation>Paris-Sud University, Le Kremlin Bicêtre, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name>
<affiliation><nlm:affiliation>University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, Eun Bong" sort="Lee, Eun Bong" uniqKey="Lee E" first="Eun Bong" last="Lee">Eun Bong Lee</name>
<affiliation><nlm:affiliation>Seoul National University, Seoul, Republic of Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nash, Peter" sort="Nash, Peter" uniqKey="Nash P" first="Peter" last="Nash">Peter Nash</name>
<affiliation><nlm:affiliation>University of Queensland, Queensland, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name>
<affiliation><nlm:affiliation>Oregon Health and Science University, Portland, Oregon, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Charles Schoeman, Christina" sort="Charles Schoeman, Christina" uniqKey="Charles Schoeman C" first="Christina" last="Charles-Schoeman">Christina Charles-Schoeman</name>
<affiliation><nlm:affiliation>University of California, Los Angeles, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thirunavukkarasu, Krishan" sort="Thirunavukkarasu, Krishan" uniqKey="Thirunavukkarasu K" first="Krishan" last="Thirunavukkarasu">Krishan Thirunavukkarasu</name>
<affiliation><nlm:affiliation>Pfizer Australia, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Demasi, Ryan" sort="Demasi, Ryan" uniqKey="Demasi R" first="Ryan" last="Demasi">Ryan Demasi</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Geier, Jamie" sort="Geier, Jamie" uniqKey="Geier J" first="Jamie" last="Geier">Jamie Geier</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwok, Kenneth" sort="Kwok, Kenneth" uniqKey="Kwok K" first="Kenneth" last="Kwok">Kenneth Kwok</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Lisy" sort="Wang, Lisy" uniqKey="Wang L" first="Lisy" last="Wang">Lisy Wang</name>
<affiliation><nlm:affiliation>Pfizer Inc, Groton, Connecticut, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Riese, Richard" sort="Riese, Richard" uniqKey="Riese R" first="Richard" last="Riese">Richard Riese</name>
<affiliation><nlm:affiliation>Pfizer Inc, Groton, Connecticut, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wollenhaupt, Jurgen" sort="Wollenhaupt, Jurgen" uniqKey="Wollenhaupt J" first="Jürgen" last="Wollenhaupt">Jürgen Wollenhaupt</name>
<affiliation><nlm:affiliation>University of Hamburg, Hamburg, Germany.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28143815</idno>
<idno type="pmid">28143815</idno>
<idno type="doi">10.1136/annrheumdis-2016-210457</idno>
<idno type="wicri:Area/PubMed/Corpus">000A04</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A04</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.</title>
<author><name sortKey="Cohen, Stanley B" sort="Cohen, Stanley B" uniqKey="Cohen S" first="Stanley B" last="Cohen">Stanley B. Cohen</name>
<affiliation><nlm:affiliation>Metroplex Clinical Research Center, Dallas, Texas, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name>
<affiliation><nlm:affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name>
<affiliation><nlm:affiliation>Paris-Sud University, Le Kremlin Bicêtre, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name>
<affiliation><nlm:affiliation>University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, Eun Bong" sort="Lee, Eun Bong" uniqKey="Lee E" first="Eun Bong" last="Lee">Eun Bong Lee</name>
<affiliation><nlm:affiliation>Seoul National University, Seoul, Republic of Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nash, Peter" sort="Nash, Peter" uniqKey="Nash P" first="Peter" last="Nash">Peter Nash</name>
<affiliation><nlm:affiliation>University of Queensland, Queensland, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name>
<affiliation><nlm:affiliation>Oregon Health and Science University, Portland, Oregon, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Charles Schoeman, Christina" sort="Charles Schoeman, Christina" uniqKey="Charles Schoeman C" first="Christina" last="Charles-Schoeman">Christina Charles-Schoeman</name>
<affiliation><nlm:affiliation>University of California, Los Angeles, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thirunavukkarasu, Krishan" sort="Thirunavukkarasu, Krishan" uniqKey="Thirunavukkarasu K" first="Krishan" last="Thirunavukkarasu">Krishan Thirunavukkarasu</name>
<affiliation><nlm:affiliation>Pfizer Australia, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Demasi, Ryan" sort="Demasi, Ryan" uniqKey="Demasi R" first="Ryan" last="Demasi">Ryan Demasi</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Geier, Jamie" sort="Geier, Jamie" uniqKey="Geier J" first="Jamie" last="Geier">Jamie Geier</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwok, Kenneth" sort="Kwok, Kenneth" uniqKey="Kwok K" first="Kenneth" last="Kwok">Kenneth Kwok</name>
<affiliation><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Lisy" sort="Wang, Lisy" uniqKey="Wang L" first="Lisy" last="Wang">Lisy Wang</name>
<affiliation><nlm:affiliation>Pfizer Inc, Groton, Connecticut, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Riese, Richard" sort="Riese, Richard" uniqKey="Riese R" first="Richard" last="Riese">Richard Riese</name>
<affiliation><nlm:affiliation>Pfizer Inc, Groton, Connecticut, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wollenhaupt, Jurgen" sort="Wollenhaupt, Jurgen" uniqKey="Wollenhaupt J" first="Jürgen" last="Wollenhaupt">Jürgen Wollenhaupt</name>
<affiliation><nlm:affiliation>University of Hamburg, Hamburg, Germany.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of the rheumatic diseases</title>
<idno type="eISSN">1468-2060</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Arthritis, Rheumatoid (drug therapy)</term>
<term>Clinical Trials as Topic</term>
<term>Female</term>
<term>Herpes Zoster (epidemiology)</term>
<term>Herpes Zoster (etiology)</term>
<term>Herpes Zoster (immunology)</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Incidence</term>
<term>Infection (epidemiology)</term>
<term>Infection (etiology)</term>
<term>Infection (immunology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasms (epidemiology)</term>
<term>Neoplasms (etiology)</term>
<term>Neoplasms (immunology)</term>
<term>Opportunistic Infections (epidemiology)</term>
<term>Opportunistic Infections (etiology)</term>
<term>Opportunistic Infections (immunology)</term>
<term>Piperidines (adverse effects)</term>
<term>Protein Kinase Inhibitors (adverse effects)</term>
<term>Pyrimidines (adverse effects)</term>
<term>Pyrroles (adverse effects)</term>
<term>Time Factors</term>
<term>Tuberculosis (epidemiology)</term>
<term>Tuberculosis (etiology)</term>
<term>Tuberculosis (immunology)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Piperidines</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyrimidines</term>
<term>Pyrroles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Herpes Zoster</term>
<term>Infection</term>
<term>Neoplasms</term>
<term>Opportunistic Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Herpes Zoster</term>
<term>Infection</term>
<term>Neoplasms</term>
<term>Opportunistic Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Herpes Zoster</term>
<term>Infection</term>
<term>Neoplasms</term>
<term>Opportunistic Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Clinical Trials as Topic</term>
<term>Female</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28143815</PMID>
<DateCreated><Year>2017</Year>
<Month>02</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>08</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>08</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>76</Volume>
<Issue>7</Issue>
<PubDate><Year>2017</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Annals of the rheumatic diseases</Title>
<ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.</ArticleTitle>
<Pagination><MedlinePgn>1253-1262</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2016-210457</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">6194 patients received tofacitinib for a total 19 406 patient-years' exposure; median exposure was 3.4 patient-years. IR (95% CI) for serious AEs was 9.4 (9.0 to 9.9); IR for serious infections was 2.7 (2.5 to 3.0). IR for (all) herpes zoster was 3.9 (3.6 to 4.2); IR for disseminated or multidermatomal herpes zoster was 0.3 (0.2 to 0.4). IR for opportunistic infections (excluding tuberculosis) was 0.3 (0.2 to 0.4) and was 0.2 (0.1 to 0.3) for tuberculosis. IR for malignancies (excluding non-melanoma skin cancer (NMSC)) was 0.9 (0.8 to 1.0); NMSC IR was 0.6 (0.5 to 0.7). IR for gastrointestinal perforations was 0.1 (0.1 to 0.2). Analysis of IR for serious infections, herpes zoster and malignancies by 6-month intervals did not reveal any notable increase in IR with longer-duration tofacitinib exposure.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This analysis of tofacitinib exposure up to 8.5 years allowed estimation of safety events with improved precision versus previous tofacitinib reports. AEs were generally stable over time; no new safety signals were observed compared with previous tofacitinib reports.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION NUMBERS" NlmCategory="UNASSIGNED">NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT00413699, NCT00661661; Results.</AbstractText>
<CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName>
<ForeName>Stanley B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo><Affiliation>Metroplex Clinical Research Center, Dallas, Texas, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tanaka</LastName>
<ForeName>Yoshiya</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mariette</LastName>
<ForeName>Xavier</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Paris-Sud University, Le Kremlin Bicêtre, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Curtis</LastName>
<ForeName>Jeffrey R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Eun Bong</ForeName>
<Initials>EB</Initials>
<AffiliationInfo><Affiliation>Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nash</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>University of Queensland, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winthrop</LastName>
<ForeName>Kevin L</ForeName>
<Initials>KL</Initials>
<AffiliationInfo><Affiliation>Oregon Health and Science University, Portland, Oregon, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Charles-Schoeman</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>University of California, Los Angeles, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thirunavukkarasu</LastName>
<ForeName>Krishan</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Pfizer Australia, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>DeMasi</LastName>
<ForeName>Ryan</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Geier</LastName>
<ForeName>Jamie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kwok</LastName>
<ForeName>Kenneth</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Lisy</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Pfizer Inc, Groton, Connecticut, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Riese</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Pfizer Inc, Groton, Connecticut, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wollenhaupt</LastName>
<ForeName>Jürgen</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>University of Hamburg, Hamburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>01</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ann Rheum Dis</MedlineTA>
<NlmUniqueID>0372355</NlmUniqueID>
<ISSNLinking>0003-4967</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>87LA6FU830</RegistryNumber>
<NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2004 Feb;50(2):372-9</RefSource>
<PMID Version="1">14872478</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2015 Jan;74(1):96-103</RefSource>
<PMID Version="1">24092417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2000 Nov 1;88(3):497-502</RefSource>
<PMID Version="1">11054684</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Rheumatology (Oxford). 2013 Jun;52(6):1052-7</RefSource>
<PMID Version="1">23365147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Autoimmun Rev. 2012 Dec;12(2):225-9</RefSource>
<PMID Version="1">22796281</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 9;367(6):508-19</RefSource>
<PMID Version="1">22873531</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2016 Jun;75(6):1024-33</RefSource>
<PMID Version="1">27002108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mod Rheumatol. 2015 Jul;25(4):514-21</RefSource>
<PMID Version="1">25496464</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Care Res (Hoboken). 2011 Mar;63(3):373-82</RefSource>
<PMID Version="1">20957659</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2015 Jun;74(6):1212-7</RefSource>
<PMID Version="1">24608401</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2009 Jul;60(7):1895-905</RefSource>
<PMID Version="1">19565475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheumatol. 2014 Nov;66(11):2924-37</RefSource>
<PMID Version="1">25047021</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Rheumatol. 2013 Jun;40(6):787-97</RefSource>
<PMID Version="1">23588946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2011 Feb;63(2):346-51</RefSource>
<PMID Version="1">20967860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Care Res (Hoboken). 2012 Dec;64(12):1819-28</RefSource>
<PMID Version="1">22730417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150-8</RefSource>
<PMID Version="1">21584942</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2014 Jan;73(1):124-31</RefSource>
<PMID Version="1">23482473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Feb 9;381(9865):451-60</RefSource>
<PMID Version="1">23294500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2014 Jan;73(1):252-5</RefSource>
<PMID Version="1">23644671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2013 Apr;72(4):517-24</RefSource>
<PMID Version="1">22562972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2016 May;75(5):831-41</RefSource>
<PMID Version="1">25902789</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheumatol. 2015 Mar;67(3):616-25</RefSource>
<PMID Version="1">25470338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2015 Jun;74(6):1311-6</RefSource>
<PMID Version="1">25398374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jun 19;370(25):2377-86</RefSource>
<PMID Version="1">24941177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Rheumatol. 2014 May;41(5):837-52</RefSource>
<PMID Version="1">24692527</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2012 Apr;64(4):970-81</RefSource>
<PMID Version="1">22006202</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2016 Apr;75(4):687-95</RefSource>
<PMID Version="1">25795907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2015 Dec;74(12):2107-16</RefSource>
<PMID Version="1">26395500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2012 Mar;64(3):617-29</RefSource>
<PMID Version="1">21952978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2013 Mar;65(3):559-70</RefSource>
<PMID Version="1">23348607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2013 Aug 20;159(4):253-61</RefSource>
<PMID Version="1">24026258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Res Ther. 2015 Apr 06;17:95</RefSource>
<PMID Version="1">25889308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1988 Mar;31(3):315-24</RefSource>
<PMID Version="1">3358796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Arthritis Rheum. 2016 Dec;46(3):261-271</RefSource>
<PMID Version="1">27443588</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2012 May;21(5):524-34</RefSource>
<PMID Version="1">22411435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2016 Jun;75(6):1133-8</RefSource>
<PMID Version="1">26318385</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2007 Dec 15;57(8):1431-8</RefSource>
<PMID Version="1">18050184</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Res Ther. 2015 Dec 15;17 :362</RefSource>
<PMID Version="1">26669566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Joint Bone Spine. 2011 May;78(3):279-84</RefSource>
<PMID Version="1">21273108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2011 Nov;70(11):1914-20</RefSource>
<PMID Version="1">21791449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Rheumatology (Oxford). 2011 Jan;50(1):124-31</RefSource>
<PMID Version="1">20675706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2007 Apr;56(4):1125-33</RefSource>
<PMID Version="1">17393394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheumatol. 2014 Oct;66(10):2675-84</RefSource>
<PMID Version="1">24943354</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2009 Feb 18;301(7):737-44</RefSource>
<PMID Version="1">19224750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2012 Apr;32(4):1119-36</RefSource>
<PMID Version="1">22493341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2007 Sep;56(9):2886-95</RefSource>
<PMID Version="1">17729297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 9;367(6):495-507</RefSource>
<PMID Version="1">22873530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2013 Mar 6;309(9):887-95</RefSource>
<PMID Version="1">23462785</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006562" MajorTopicYN="N">Herpes Zoster</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infection</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009894" MajorTopicYN="N">Opportunistic Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular Disease</Keyword>
<Keyword MajorTopicYN="N">Infections</Keyword>
<Keyword MajorTopicYN="N">Rheumatoid Arthritis</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
<Keyword MajorTopicYN="N">Tuberculosis</Keyword>
</KeywordList>
<CoiStatement>Competing interests: SBC, KLW, CC-S and JW have served as consultants for, and have received speaker fees and honoraria from, Pfizer Inc. YT has served as a consultant for, and has received speaker fees and honoraria from, AbbVie, Asahi-kasei, Astellas Pharma, BMS, Chugai Pharma, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Janssen, Mitsubishi-Tanabe, Pfizer Inc, Sanofi, Takeda, Teijin and YL Biologics. XM has served as a consultant for, and has received speaker fees and honoraria from, BMS, GlaxoSmithKline, Pfizer Inc and UCB. EBL has served as a consultant for Pfizer Inc. KT, RDM, JG, KK and LW are employees and shareholders of Pfizer Inc. RR was an employee of Pfizer Inc at the time these analyses were conducted and holds stock/stock options in Pfizer Inc.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>09</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>12</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>12</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>2</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>8</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>2</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28143815</ArticleId>
<ArticleId IdType="pii">annrheumdis-2016-210457</ArticleId>
<ArticleId IdType="doi">10.1136/annrheumdis-2016-210457</ArticleId>
<ArticleId IdType="pmc">PMC5530353</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A04 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A04 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:28143815
   |texte=   Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:28143815" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki